ConductScience.org, home

Paper33333207

Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.

Higashi-Kuwata N and 16 others. J Hepatol, 2021. Cited by 26 papers, by iCite.

Cite this record

ConductScience Library. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. Papers, record 33333207. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33333207

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
PubMed
Journal
J Hepatol
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
1.65
iCite
Revised in PubMed
2025-05-30
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Higashi-Kuwata NNobuyo
2Hayashi SSanae
3Kumamoto HHiroki
4Ogata-Aoki HHiromi
5Das DDebananda
6Venzon DDavid
7Hattori SIShin-Ichiro
8Bulut HHaydar
9Hashimoto MMai
10Otagiri MMasaki
11Takamune NNobutoki
12Kishimoto NNaoki
13Davis DADavid A
14Misumi SShogo
15Kakuni MMasakazu
16Tanaka YYasuhito
17Mitsuya HHiroaki

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug DevelopmentMajor topic
Drug Resistance, ViralMajor topic
Hepatitis BMajor topic
Hepatitis B virusMajor topic
Reverse Transcriptase InhibitorsMajor topic
Animals
Delayed-Action Preparations
Disease Models, Animal
Drug Administration Routes
Drug Administration Schedule
Humans
Mice
RNA-Directed DNA Polymerase
Time

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
ZIA BC011486Intramural NIH HHSUnited StatesZIABC011486PubMed and NIHNIH RePORTER
ZIDSC007202NIHNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in33715896Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection?https://conductscience.org/library/papers/33715896

Source PubMed

Download CSV of comments and corrections

References17

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1261222734'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.Hepatology2015https://conductscience.org/library/papers/26122273PubMed
227489345Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA).Proc Natl Acad Sci U S A2016https://conductscience.org/library/papers/27489345PubMed
329877316Hepatitis B virus infection.Nat Rev Dis Primers2018https://conductscience.org/library/papers/29877316PubMed
418056280Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.Antimicrob Agents Chemother2008https://conductscience.org/library/papers/18056280PubMed
510815717Stability study of selected adenosine nucleosides using LC and LC/MS analyses.J Pharm Biomed Anal2000https://conductscience.org/library/papers/10815717PubMed
62106581Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV.J Med Chem1990https://conductscience.org/library/papers/2106581PubMed
717050790Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects.J Clin Pharmacol2006https://conductscience.org/library/papers/17050790PubMed
831266626Drugs in the Pipeline for HBV.Clin Liver Dis2019https://conductscience.org/library/papers/31266626PubMed
931168360Treatment for Advanced Hepatocellular Carcinoma: Current Standard and the Future.Clin Liver Dis (Hoboken)2019https://conductscience.org/library/papers/31168360PubMed
1031266617WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective.Clin Liver Dis2019https://conductscience.org/library/papers/31266617PubMed
1130670420CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.Antimicrob Agents Chemother2019https://conductscience.org/library/papers/30670420PubMed
1226515673Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones.J Infect2016https://conductscience.org/library/papers/26515673PubMed
132477299Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase.Gastroenterology1989https://conductscience.org/library/papers/2477299PubMed
142436223
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.
Proc Natl Acad Sci U S A1987https://conductscience.org/library/papers/2436223PubMed
1516968952Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.Pharmacol Rev2006https://conductscience.org/library/papers/16968952PubMed
1627916488Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter.Drug Metab Pharmacokinet2017https://conductscience.org/library/papers/27916488PubMed
1717548498Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.Antimicrob Agents Chemother2007https://conductscience.org/library/papers/17548498PubMed

Download CSV of references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
40872772The Evolution of Cell Culture Systems to Study Hepatitis B Virus Pathogenesis and Antiviral Susceptibility.Viruses2025https://conductscience.org/library/papers/40872772PubMed
39831159An orally available P1'-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier.PNAS Nexus2025https://conductscience.org/library/papers/39831159PubMed
39107264Colchicine-mediated selective autophagic degradation of HBV core proteins inhibits HBV replication and HBV-related hepatocellular carcinoma progression.Cell Death Discov2024https://conductscience.org/library/papers/39107264PubMed
38977798Deviated binding of anti-HBV nucleoside analog E-CFCP-TP to the reverse transcriptase active site attenuates the effect of drug-resistant mutations.Sci Rep2024https://conductscience.org/library/papers/38977798PubMed
38549051Predictors of antiretroviral treatment failure to the first line therapy: a cross-sectional study among Iranian HIV-positive adults.BMC Infect Dis2024https://conductscience.org/library/papers/38549051PubMed
38042824The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges.Chin Med2023https://conductscience.org/library/papers/38042824PubMed
37627273Chronic Hepatitis B Infection: New Approaches towards Cure.Biomolecules2023https://conductscience.org/library/papers/37627273PubMed
37265996Synthesis of novel entecavir analogues having 4'-cyano-6''-fluoromethylenecyclopentene skeletons as an aglycone moiety as highly potent and long-acting anti-hepatitis B virus agent.RSC Adv2023https://conductscience.org/library/papers/37265996PubMed
36933835A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes.Virus Res2023https://conductscience.org/library/papers/36933835PubMed
36906663Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure.Drugs2023https://conductscience.org/library/papers/36906663PubMed
36841831Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2.Nat Commun2023https://conductscience.org/library/papers/36841831PubMed
36563152An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression.Sci Adv2022https://conductscience.org/library/papers/36563152PubMed
36410388Long-Acting Treatments for Hepatitis B.Clin Infect Dis2022https://conductscience.org/library/papers/36410388PubMed
36344041Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters.J Pharmacol Sci2022https://conductscience.org/library/papers/36344041PubMed
36338434Potent and biostable inhibitors of the main protease of SARS-CoV-2.iScience2022https://conductscience.org/library/papers/36338434PubMed
35891374Drug Discovery Study Aimed at a Functional Cure for HBV.Viruses2022https://conductscience.org/library/papers/35891374PubMed
35308231A Polysaccharide From Eupolyphaga sinensis Walker With Anti-HBV Activities In Vitro and In Vivo.Front Pharmacol2022https://conductscience.org/library/papers/35308231PubMed
35045629[A possible mechanism for low-level viremia occurrence in nucleos(t)ide analog-treated chronic hepatitis B patients].Zhonghua Gan Zang Bing Za Zhi2021https://conductscience.org/library/papers/35045629PubMed
34829806The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target.Biomedicines2021https://conductscience.org/library/papers/34829806PubMed
33572409Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday.Molecules2021https://conductscience.org/library/papers/33572409PubMed

Download CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
IFNA13439PubTator's text mininghttps://conductscience.org/library/genes/3439NCBI Gene
IFNL1282618PubTator's text mininghttps://conductscience.org/library/genes/282618NCBI Gene
IFNL2282616PubTator's text mininghttps://conductscience.org/library/genes/282616NCBI Gene
IFNL3282617PubTator's text mininghttps://conductscience.org/library/genes/282617NCBI Gene
PLAU5328PubTator's text mininghttps://conductscience.org/library/genes/5328NCBI Gene
TAF8129685PubTator's text mininghttps://conductscience.org/library/genes/129685NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33333207

GET https://conductscience.org/api/papers/v1/33333207/authors